The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Factors associated with progression to myelofibrosis in patients with essential thrombocythemia
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, discusses features that are suggestive of progression to myelofibrosis (MF) in patients with essential thrombocythemia (ET). He mentions the duration of disease, leukocytosis, JAK2 mutations, and fibrosis as factors that are associated with an increased risk of progression. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Promedior, Incyte, Genetech, Abbvie, Samus, Celgene, Constellation, CTI BioPharma.- a Sobi Company, Mays Cancer Center, NCI
Consultancy: Constellation, LaJolla Pharma, Sierra Onc, Novartis.
